Ono Pharmaceutical Co., Ltd.
Other OTCTotal Valuation
Ono Pharmaceutical Co., Ltd. carries a market capitalization of 6.84B, placing it among publicly traded companies globally. Its enterprise value stands at 977.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.84B |
| Enterprise Value | 977.61B |
Share Statistics
Ono Pharmaceutical Co., Ltd. currently has 469.71M shares outstanding.
| Shares Outstanding | 469.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Ono Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 18.54. The price-to-sales ratio is 4.06, and the price-to-book ratio stands at 1.22.
| PE Ratio | 18.54 |
| PS Ratio | 4.06 |
| PB Ratio | 1.22 |
| P/TBV Ratio | 2.35 |
| P/FCF Ratio | 11.55 |
| P/OCF Ratio | 13.41 |
Enterprise Valuation
On an enterprise value basis, Ono Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 15.54 and an EV/FCF ratio of 11.29. The EV/Sales ratio of 4.01 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.54 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.01 |
| EV / EBITDA | 15.54 |
| EV / EBIT | 15.54 |
| EV / FCF | 11.29 |
Financial Position
Ono Pharmaceutical Co., Ltd. maintains a current ratio of 3.22, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.51, indicating elevated leverage, while an interest coverage ratio of 71.72 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.22 |
| Quick Ratio | 1.45 |
| Debt / Equity | 20.51 |
| Debt / EBITDA | 2.57 |
| Interest Coverage | 71.72 |
Financial Efficiency
Ono Pharmaceutical Co., Ltd. posts a return on equity of 6.71 and a return on invested capital of 5.86.
| Return on Equity (ROE) | 6.71 |
| Return on Assets (ROA) | 5.51 |
| Return on Invested Capital (ROIC) | 5.86 |
| Return on Capital Employed (ROCE) | 6.10 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.24 |
Taxes
Over the trailing twelve months, Ono Pharmaceutical Co., Ltd. has paid 10.92B in income taxes, reflecting an effective tax rate of 16.94.
| Income Tax | 10.92B |
| Effective Tax Rate | 16.94 |
Stock Price Statistics
Ono Pharmaceutical Co., Ltd.'s stock has gained approximately 40.17341% over the past 52 weeks. The 50-day moving average sits at 14.50, while the 200-day moving average is 13.45.
| Beta (5Y) | N/A |
| 52-Week Price Change | 40.17341% |
| 50-Day Moving Average | 14.50 |
| 200-Day Moving Average | 13.45 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Ono Pharmaceutical Co., Ltd. generated 243.96B in revenue and converted that into 53.49B in net income, yielding earnings per share of 113.17. EBITDA reached 62.90B, while operating income came in at 62.90B.
| Revenue | 243.96B |
| Gross Profit | 181.60B |
| Operating Income | 62.90B |
| Pretax Income | 64.44B |
| Net Income | 53.49B |
| EBITDA | 62.90B |
| EBIT | 62.90B |
| Earnings Per Share (EPS) | 113.17 |
Balance Sheet
Ono Pharmaceutical Co., Ltd. holds 181.13B in cash and equivalents against 161.66B in total debt, resulting in a net debt position of -17.09B. Total book value stands at 810.33B, with working capital of 276.75B providing operational flexibility.
| Cash & Cash Equivalents | 181.13B |
| Total Debt | 161.66B |
| Net Debt | -17.09B |
| Equity (Book Value) | 810.33B |
| Book Value Per Share | 1,714.07 |
| Working Capital | 276.75B |
Cash Flow
Ono Pharmaceutical Co., Ltd. produced 73.94B in operating cash flow over the past twelve months. After subtracting -11.94B in capital expenditures, free cash flow totaled 62.00B - equivalent to 131.15 per share.
| Operating Cash Flow | 73.94B |
| Capital Expenditures | -11.94B |
| Free Cash Flow | 62.00B |
| FCF Per Share | 131.15 |
Margins
Ono Pharmaceutical Co., Ltd. operates with a gross margin of 74.44, reflecting its pricing power and cost economics. The operating margin of 25.78 and net profit margin of 21.92 provide insight into operational efficiency.
| Gross Margin | 74.44 |
| Operating Margin | 25.78 |
| Pretax Margin | 26.41 |
| Profit Margin | 21.92 |
| EBITDA Margin | 25.78 |
Dividends & Yields
The company's payout ratio of 35.73 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 40.47 |
| Dividend Yield | N/A |
| Payout Ratio | 35.73 |
| Shareholder Yield | 4.36 |
| FCF Yield | 8.66 |
Stock Splits
Ono Pharmaceutical Co., Ltd.'s most recent stock split took place on March 29, 2016 with a 1:5 split ratio.
| Last Split Date | 3/29/2016 |
| Split Ratio | 1:5 |
Scores
Ono Pharmaceutical Co., Ltd. posts an Altman Z-Score of 5.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.09 |